Antiallergic Effect of Hizikia fusiformis in an Ovalbumin-Induced Allergic Rhinitis Mouse Model
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Objectives. The extract of Hizikia fusiformis is known to exhibit anticancer, antiatopic and antioxidant activities. We aimed to investigate the extract of H. fusiformis on allergic rhinitis inflammation in a mouse model. Methods. The 4-week-old BALB/c mice were randomly assigned into four groups: group A, control group (n=9); group B, allergic rhinitis group (n=10); group C (n=10) received 300 mg/kg of H. fusiformis during nasal challenging period; group D (n=10) received 600 mg/kg of H. fusiformis during general sensitization period and 300 mg/kg of H. fusiformis during nasal challenging period. Allergic inflammation was made with ovalbumin (OVA) and alum then challenged intranasally with OVA. H. fusiformis was intraperitoneally administered 3 hours before the OVA administration. Allergic symptom score and the levels of immunoglobulin G1 (IgG1), IgG2a, OVA-specific IgE antibodies, levels of cytokines in the nasal mucosa and in spleen cell culture supernatant, such as tumor necrosis factor alpha (TNF-α), interleukin 4 (IL-4), IL-5, IL-13, and IL-10 were assessed. The percentage of regulatory T cell was analyzed by flow cytometry. Eosinophilic infiltration and goblet cell hyperplasia were also evaluated. Results. H. fusiformis administered groups C and D showed significant inhibitory effects on nasal symptoms, IL-13 mRNA expression and eosinophil infiltration/goblet cell hyperplasia in the nasal tissue; OVA-specific IgE production in serum (P<0.05). In group D, H. fusiformis treatment downregulated IL-4, IL-5, IL-13, TNF-α, and IL-10 cytokine expression in splenocyte culture as well as significantly decreased IgG2a, IgG1 levels in serum compared with group B (P<0.05). However, the expressions of IL-5, interferon-γ and forkhead box P3 mRNA did not change in groups C and D. Conclusion. H. fusiformis could induce antiallergic inflammation by suppressing the T-helper type 2 cytokine production (IL-13) locally and systemically, OVA-specific IgE formation, goblet cell hyperplasia, and eosinophilic infiltration in a mouse model of allergic rhinitis. Thus, H. fusiformis could be considered as a potential therapeutic agent in treating allergic rhinitis.
Abstract
Objectives. The extract of Hizikia fusiformis is known to exhibit anticancer, antiatopic and antioxidant activities. We aimed to investigate the extract of H. fusiformis on allergic rhinitis inflammation in a mouse model. Methods. The 4-week-old BALB/c mice were randomly assigned into four groups: group A, control group (n=9); group B, allergic rhinitis group (n=10); group C (n=10) received 300 mg/kg of H. fusiformis during nasal challenging period; group D (n=10) received 600 mg/kg of H. fusiformis during general sensitization period and 300 mg/kg of H. fusiformis during nasal challenging period. Allergic inflammation was made with ovalbumin (OVA) and alum then challenged intranasally with OVA. H. fusiformis was intraperitoneally administered 3 hours before the OVA administration. Allergic symptom score and the levels of immunoglobulin G1 (IgG1), IgG2a, OVA-specific IgE antibodies, levels of cytokines in the nasal mucosa and in spleen cell culture supernatant, such as tumor necrosis factor alpha (TNF-α), interleukin 4 (IL-4), IL-5, IL-13, and IL-10 were assessed. The percentage of regulatory T cell was analyzed by flow cytometry. Eosinophilic infiltration and goblet cell hyperplasia were also evaluated. Results. H. fusiformis administered groups C and D showed significant inhibitory effects on nasal symptoms, IL-13 mRNA expression and eosinophil infiltration/goblet cell hyperplasia in the nasal tissue; OVA-specific IgE production in serum (P<0.05). In group D, H. fusiformis treatment downregulated IL-4, IL-5, IL-13, TNF-α, and IL-10 cytokine expression in splenocyte culture as well as significantly decreased IgG2a, IgG1 levels in serum compared with group B (P<0.05). However, the expressions of IL-5, interferon-γ and forkhead box P3 mRNA did not change in groups C and D. Conclusion. H. fusiformis could induce antiallergic inflammation by suppressing the T-helper type 2 cytokine production (IL-13) locally and systemically, OVA-specific IgE formation, goblet cell hyperplasia, and eosinophilic infiltration in a mouse model of allergic rhinitis. Thus, H. fusiformis could be considered as a potential therapeutic agent in treating allergic rhinitis.
참고문헌 (33)
- Shan BE, "Immunomodulating activity of seaweed extract on human lymphocytes in vitro", Int J Immunopharmacol, 21(1), pp.59~70 (1999)
- Gyu-Won Huh, "Fucosterols from Hizikia fusiformis and Their Proliferation Activities on Osteosarcoma-derived Cell MG63", Applied Biological Chemistry, 55(4), pp.551~555 (2012), 한국응용생명화학회[DOI]
- Yang EJ, "Inhibitory effect of Jeju endemic seaweeds on the production of pro-inflammatory mediators in mouse macrophage cell line RAW 264.7.", J Zhejiang Univ Sci B, 11(5), pp.315~322 (2010)
- Kang CH, "Ethyl alcohol extract of Hizikia fusiforme induces caspase-dependent apoptosis in human leukemia U937 cells by generation of reactive oxygen species", Trop J Pharm Res, 10(6), pp.739~746 (2011)
- Wu M, "Evaluation of antioxidant activities of water-soluble polysaccharides from brown alga Hizikia fusiformis", Int J Biol Macromol, 56, pp.28~33 (2013)
- Choi EY, "Protective effects of a polysaccharide from Hizikia fusiformis against ethanol toxicity in rats", Food Chem Toxicol, 47(1), pp.134~139 (2009)
- Sharma BR, "Anti-inflammatory effects and mechanisms of Hizikia fusiformis via multicellular signaling pathways in lipopolysaccharide-induced RAW 264.7 cells", Pak J Pharm Sci, 30(1), pp.43~48 (2017)
- 이슬기, "Inhibitory Effect of Hizikia fusiformis Solvent-Partitioned Fractions on Invasion and MMP Activity of HT1080 Human Fibrosarcoma Cells", Preventive Nutrition and Food Science, 22(3), pp.184~190 (2017), 한국식품영양과학회[DOI]
- Lee KH, "Hizikia fusiformis fractions successfully improve atopic dermatitis indices in anti-CD3-stimulated splenocytes and 2, 4-dinitrochlorobenzene-treated BALB", c mice, 2014, pp.66(3), 466~476
- "A pharmaceutical composition for alleviation, prevention or treatment of metabolic bone disease comprising an extract of fermented hizikia fusiforme and health functional food comprising the same" (2013)[URL]
- 이지은, "Antiallergic Function of KR62980, a Peroxisome Proliferator- Activated Receptor-γ Agonist, in a Mouse Allergic Rhinitis Model", Allergy, Asthma & Immunology Research, 7(3), pp.256~264 (2015), 대한천식알레르기학회
- Saito H, "Pathogenesis of murine experimental allergic rhinitis : a study of local and systemic consequences of IL-5 deficiency", J Immunol, 168(6), pp.3017~3023 (2002)
- Hellings PW, "Eosinophilic rhinitis accompanies the development of lower airway inflammation and hyper-reactivity in sensitized mice exposed to aerosolized allergen", Clin Exp Allergy, 31(5), pp.782~790 (2001)
- Hussain I, "Induction, distribution and modulation of upper airway allergic inflammation in mice", Clin Exp Allergy, 31(7), pp.1048~1059 (2001)
- Wills-Karp M, "Interleukin-13 : central mediator of allergic asthma", Science, 282(5397), pp.2258~2261 (1998)
- Eifan AO, "Pathogenesis of rhinitis", Clin Exp Allergy, 46(9), pp.1139~1151 (2016)
- Hirano M, "Essential role of macrophages in the initiation of allergic rhinitis in mice sensitized intranasally once with cedar pollen : regulation of class switching of immunoglobulin in B cells by controlling interleukin-4 production in T cells of submandibular lymph nodes", Microbiol Immunol, 56(6), pp.392~405 (2012)
- Artis D, "Tumor necrosis factor alpha is a critical component of interleukin 13-mediated protective T helper cell type 2 responses during helminth infection", J Exp Med, 190(7), pp.953~962 (1999)
- Kim J, "Anti-tumor necrosis factor-alpha antibody treatment reduces pulmonary inflammation and methacholine hyper-responsiveness in a murine asthma model induced by house dust", Clin Exp Allergy, 36(1), pp.122~132 (2006)
- Iwasaki M, "TNF-alpha contributes to the development of allergic rhinitis in mice", J Allergy Clin Immunol, 112(1), pp.134~140 (2003)
- Mo JH, "Anti-tumor necrosis factor-alpha treatment reduces allergic responses in an allergic rhinitis mouse model", Allergy, 66(2), pp.279~286 (2011)
- Kanehiro A, "Tumor necrosis factor-alpha negatively regulates airway hyperresponsiveness through gamma-delta T cells", Am J Respir Crit Care Med, 164(12), pp.2229~2238 (2001)
- Pellerin L, "Regulatory T cells and their roles in immune dysregulation and allergy", Immunol Res, 58(2-3), pp.358~368 (2014)
- Grindebacke H, "Defective suppression of Th2 cytokines by CD4CD25 regulatory T cells in birch allergics during birch pollen season", Clin Exp Allergy, 34(9), pp.1364~1372 (2004)
- Ling EM, "Relation of CD4+CD25+ regulatory T-cell suppression of allergendriven T-cell activation to atopic status and expression of allergic disease", Lancet, 363(9409), pp.608~615 (2004)
- Kinoshita T, "Natural regulatory T cells in isolated early responders compared with dual responders with allergic asthma", J Allergy Clin Immunol, 133(3), pp.696~703 (2014)
- Lee JH, "The levels of CD4+CD25+ regulatory T cells in paediatric patients with allergic rhinitis and bronchial asthma", Clin Exp Immunol, 148(1), pp.53~63 (2007)
- Lin YL, "The functional insufficiency of human CD4+CD25 high T-regulatory cells in allergic asthma is subjected to TNF-alpha modulation", Allergy, 63(1), pp.67~74 (2008)
- Moniuszko M, "Frequencies of circulating CD4+CD25+CD127low cells in atopics are altered by bronchial allergen challenge", Eur J Clin Invest, 38(3), pp.201~204 (2008)
- Hartl D, "Quantitative and functional impairment of pulmonary CD4+CD25hi regulatory T cells in pediatric asthma", J Allergy Clin Immunol, 119(5), pp.1258~1266 (2007)
- Thunberg S, "Allergen provocation increases TH2-cytokines and FOXP3expression in the asthmatic lung", Allergy, 65(3), pp.311~318 (2010)
- Smyth LJ, "Increased airway T regulatory cells in asthmatic subjects", Chest, 138(4), pp.905~912 (2010)
- Noval Rivas M, "Regulatory T cells in allergic diseases", J Allergy Clin Immunol, 138(3), pp.639~652 (2016)